Literature DB >> 17605752

Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient.

S Y C Tong1, A Y Peleg, J Yoong, R Handke, J Szer, M Slavin.   

Abstract

Breakthrough invasive fungal infections among patients with hematologic malignancies receiving voriconazole are being reported with increasing frequency, with zygomycete infections predominating. We report a case of disseminated Scedosporium prolificans infection in a patient receiving voriconazole prophylaxis. Despite poor in vitro activity of voriconazole for this organism, synergy studies using the checkerboard method demonstrated synergy with the combination of voriconazole and terbinafine. This regimen, in conjunction with central venous line removal and intravitreal voriconazole, contributed to the recovery of the patient. S. prolificans is a life-threatening mold that should be considered in patients with breakthrough invasive fungal infections while on voriconazole prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17605752     DOI: 10.1111/j.1399-3062.2007.00203.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  6 in total

1.  Mucormycosis in Mato Grosso, Brazil: a case reports, caused by Rhizopus microsporus var. oligosporus and Rhizopus microsporus var. rhizopodiformis.

Authors:  Luciano Corrêa Ribeiro; Bodo Wanke; Manuela da Silva; Luciana Basili Dias; Renato Mello; Fernando Artur Pena Borges Canavarros; Diniz Pereira Leite; Rosane Christine Hahn
Journal:  Mycopathologia       Date:  2011-09-28       Impact factor: 2.574

Review 2.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

3.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

Review 4.  Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis.

Authors:  Carsten Schwarz; Dominik Hartl; Olaf Eickmeier; Andreas Hector; Christian Benden; Isabelle Durieu; Amparo Sole; Silvia Gartner; Carlos E Milla; Peter James Barry
Journal:  Mycopathologia       Date:  2017-07-31       Impact factor: 2.574

Review 5.  Rare fungal infectious agents: a lurking enemy.

Authors:  Anna Skiada; Ioannis Pavleas; Maria Drogari-Apiranthitou
Journal:  F1000Res       Date:  2017-10-31

6.  Pseudallescheria boydii with Aspergillus fumigatus and Aspergillus terreus in a Critically Ill Hematopoietic Stem Cell Recipient with ARDS.

Authors:  Tobias Lahmer; Marlena Messer; Ursula Ehmer; Stefan Eser; Analena Beitz; Lisa Fekecs; Roland M Schmid; Wolfgang Huber
Journal:  Mycopathologia       Date:  2015-10-11       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.